T1	intervention 21 44	circulating adiponectin
T2	intervention 85 94	tamoxifen
T3	intervention 99 110	fenretinide
T4	eligibility 465 510	premenopausal women at risk for breast cancer
T5	control 967 974	placebo
T6	duration 982 988	2-year
T7	No-of-participants 730 733	235
T8	outcome 1059 1099	mammographic density and HDL cholesterol
T9	outcome 1214 1232	adiponectin levels
T10	outcome 1337 1361	breast neoplastic events
T11	outcome 1571 1589	adiponectin levels
T12	duration 1311 1320	7.2 years
T13	outcome-Measure 524 542	circulating lipids
T14	outcome-Measure 544 572	insulin-like growth factor 1
T15	outcome-Measure 574 581	glucose
T16	outcome-Measure 583 614	insulin and insulin sensitivity
T17	outcome-Measure 675 680	eptin
T18	outcome-Measure 682 693	adiponectin
T19	outcome-Measure 699 726	leptin-to-adiponectin ratio
T20	eligibility 734 870	premenopausal women with pT1mic/pT1a breast cancer (n = 21), intraepithelial neoplasia (n = 160), or 5-year Gail risk of 1.3% or greater
